EuroBiotech: More Articles of Note

Newspapers

> Transgene raised €14.4 million ($16.9 million) from U.S. and European investors. The financing extends the French immuno-oncology player’s financial runway out to the middle of 2019. Release  

> ProQr priced a $20 million public offering. The Dutch biotech plans to split the cash fairly evenly between three pipeline prospects: QR-110, QR-313 and QRX-421. Statement

> Mereo BioPharma received EMA PRIME designation for BPS-804 in osteogenesis imperfecta. The regulatory status positions the ex-Novartis’ asset to benefit from an accelerated assessment if it makes it as far as a filing for approval. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Immunocore posted data on its bispecific T cell redirector IMCgp100 in patients with metastatic uveal melanoma. Two of the 19 patients in the intra-patient dose escalation had objective responses to treatment. But, despite that low rate, 73% were alive after one year. That compares favorably to the survival rates in patients treated with other regimens. Statement

> Motif Bio secured up to $20 million in debt financing. The facility, which has a 10% interest rate tied to the U.S. prime rate, gives Motif Bio the cash to prepare for the planned commercialization of its antibiotic in 2019. Release

> The full exercising of the underwriters’ option on additional shares pushed Erytech’s IPO haul up to $144 million. That sees Erytech join Ablynx, which raised $230 million, toward the top of the list of the largest Nasdaq biotech IPOs of the year. Statement

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.